Currently, trials are underway to stratify hormone receptor-positive, early breast cancer patients by their gene expression profile into those with a low or high risk of recurrence [15], which in turn influences the decision to administer chemotherapy. The gene discussed is NR4A1; the disease is breast carcinoma.